Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

The invention encompasses a pharmaceutical composition comprising a therapeutically effective amount of a cyclooxygenase-2 selective inhibitor selected from rofecoxib and etoricoxib or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a proton pump inhibitor selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole, or a pharmaceutically acceptable salt of any of the aforementioned, in combination with a pharm...

Disclosed is a solid oral dosage pharmaceutical tablet comprising a first layer including at least one opioid, the first layer disposed between two adjacent controlled release layers, at least one of said adjacent controlled release layers including at least one non-opioid analgesic, wherein: a. the two adjacent controlled release layers cover substantially the entire first layer around a peripheral edge thereof, and/or b. a portion of the two adjacent controlled release layers are joined into a...

The present invention is directed to a method of treating disorders in which TFNalpha activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha (hTNFalpha) in combination with another drug which is useful for treating the disorder. The other drug can be prednisone, folic acid, celexoxib, rofecoxib, paracetamol, naproxen, tramadol, ibuprofen, Di-gesic, diclofenac, meth...

Mixture (X) of at least one analgesic (A) and an inhibitor (B) of cyclo-oxygenase II (COXII). Mixture (X) of at least one analgesic (A) and an inhibitor (B) of cyclo-oxygenase II (COXII) where (A) is a phenyl-substituted tertiary amine of formulae (I)-(III) as racemates pure or mixed stereoisomers (particularly enantiomers or diastereoisomers) optionally in the form of acids bases salts or solvates preferably hydrates. [Image] X hydroxy fluoro chloro hydrogen or OCOR7gt;; R1gt;1-4C linear branc...

Composiciones farmacéuticas para el tratamiento y/o prevencion de la osteoartritis en mamíferos particularmente humanos que comprenden bicarbonato de sodio y gluconato de calcio y opcionalmente comprende uno o más componentes adicionales. La invencion además proporciona métodos de tratamiento o prevencion de la osteoartritis por administracion a un mamífero preferiblemente por vía de inyeccion intrarticular de una o más composiciones de la invencion. Reivindicacion 13 La composicion farm...

Reivindicacion 1 Un dispositivo de ruptura de liberacion controlada caracterizado porque comprende a) un nucleo que comprende al menos un agente activo y al menos un excipiente; b) una membrana semipermeable que encierra al nucleo y que comprende al menos un pasaje preformado que la atraviesa y una region debilitada; y c) una subcapa que controla la ruptura entre el nucleo y la membrana semipermeable donde la membrana semipermeable se rompe en una region debilitada durante el uso debido al incre...

The patent application relates to chemical compounds with a basic structure selected from salicylic acid acetylsalicylic acid APHS (o-acetoxyphenylhept-2-inylsulfid) salen ligands diflunisal salsalate benorylate phenylalkanylcarbon acids (particularly fenoprofen ibuprofen ketoprofen flurbiprofen naproxen tolmetin sulindac indomethacin diclofenac carprofen etodolac ketorolac) oxicam inhibitors (particularly Tenoxicam Prioxicam Meloxicam) anthranilic acids: (particularly mefenamic acid meclofenami...